Related Experiment Video
Updated: Jan 23, 2026

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
Published on: August 1, 2013
Erdafitinib: First Global Approval
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Abstract:
Erdafitinib (Balversa™, Janssen Pharmaceutical Companies) is a pan-fibroblast growth factor receptor (FGFR) inhibitor that was recently approved in the USA for the treatment of locally advanced or metastatic FGFR3 or FGFR2 urothelial carcinoma. The drug is also being investigated as a treatment for other cancers including cholangiocarcinoma, liver cancer, non-small cell lung cancer, prostate cancer, lymphoma and oesophageal cancer. This article summarizes the milestones in the development of erdafitinib leading to this first approval for the treatment of urothelial carcinoma.
Insights
Erdafitinib is a new FGFR inhibitor approved for advanced urothelial carcinoma. Its development milestones are summarized, highlighting its potential in treating various cancers.
Area of Science:
- Oncology
- Pharmacology
- Cancer Therapeutics
Background:
- Erdafitinib is a pan-fibroblast growth factor receptor (FGFR) inhibitor.
- It targets FGFR3 and FGFR2 mutations common in certain cancers.
- Urothelial carcinoma is a significant indication for FGFR inhibitors.
Purpose of the Study:
- To summarize the key development milestones of erdafitinib.
- To document the journey leading to its first regulatory approval.
- To highlight erdafitinib's role in treating urothelial carcinoma.
Main Methods:
- Review of preclinical and clinical development data.
- Analysis of regulatory submission and approval processes.
- Summary of key research findings and trial outcomes.
Main Results:
- Erdafitinib received US FDA approval for urothelial carcinoma.
- The drug targets locally advanced or metastatic FGFR3/FGFR2-altered urothelial carcinoma.
- Ongoing investigations explore its efficacy in other cancer types.
Conclusions:
- Erdafitinib represents a significant advancement in targeted cancer therapy.
- Its approval marks a milestone for patients with specific genetic alterations in urothelial carcinoma.
- Further research is warranted to explore its broader application in oncology.
Related Concept Videos
FDA Approved Drugs: Changes to Approved Drugs
Global Climate Change
Introduction to Global Positioning System
Global Regulatory Systems
Errors in Global Positioning System
Field Application of Global Positioning System

